Effects of a novel dispersible supplement containing 2500IU of vitamin D and 1000µg of B12 in restoring vitamin D and B12 insufficiency

icholaos Angelopoulos,MD,Phd0 个研究点目标入组 150 人开始时间: 2024年4月16日最近更新: 2024年4月22日

适应症

试验速览

暂无简介。

•Patients with serum vitamin d levels lower than 25 ng/dl and b12 levels lower than 250 ng/

•1.individuals who have been taking vitamin D supplements regularly or at high doses prior to the study.
•2.Medications affecting vitamin D metabolism: Exclude individuals who are taking medications known to interfere with vitamin D metabolism or absorption, such as antiepileptic drugs (phenytoin, phenobarbital), glucocorticoids (prednisone), or certain weight-loss medications (orlistat).
•3.Chronic kidney disease
•4.Other metabolic disorders: individuals with specific metabolic disorders that could impact vitamin D metabolism or lead to altered vitamin D levels, such as primary hyperparathyroidism, hyperthyroidism, or malabsorption syndromes (e.g., celiac disease, Crohn's disease).
•5.Conditions that significantly affect bone health, such as osteoporosis, osteomalacia, or Paget's disease.
•6.Pregnancy and breastfeeding
•7.Severe illnesses or comorbidities: terminal cancer, uncontrolled diabetes, or autoimmune disorders.
•8. Drugs that affect vitamin b12 metabolism: Drugs
•Nitrous oxide
•Proton pump inhibitors
•H2 receptor antagonists
•Metformin
•Colchicine
•Slow K (potassium chloride) preparations
•Cholestyramine
•9. History of bariatric surgery and/or stomach operation

发起方

icholaos Angelopoulos,MD,Phd